Lipella Pharmaceuticals INC

Lipella Pharmaceuticals Inc. has filed for Chapter 11 bankruptcy and entered into an Asset Purchase Agreement to sell substantially all of its assets.

Lori A. Birder has resigned from Lipella Pharmaceuticals Inc.'s Board of Directors, effective immediately, with no reported disagreements.

Dr. Naoki Yoshimura will retire from Lipella Pharmaceuticals Inc.'s Board of Directors effective December 31, 2025.

Dr. Michael Chancellor will retire from his Chief Medical Officer and Board of Directors roles at Lipella Pharmaceuticals Inc. effective December 4, 2025.

Lipella Pharmaceuticals announced positive final results from its Phase 2a study of LP-10 for oral lichen planus, meeting safety and efficacy endpoints.

Lipella Pharmaceuticals Inc. issued a letter to stockholders addressing its recent Nasdaq delisting, reaffirming operational strength, and detailing plans to relist on a national exchange while advancing its clinical pipeline.

Lipella Pharmaceuticals reported increased net losses and significant cash burn for Q3 2025, raising substantial doubt about its ability to continue as a going concern, following its delisting from Nasdaq.

Lipella Pharmaceuticals Inc. reported increased net losses and was delisted from Nasdaq, raising substantial doubt about its ability to continue as a going concern, despite clinical progress.

Lipella Pharmaceuticals announces its Q1 2025 financial results, showing a net loss of $1.31 million and ongoing efforts to maintain Nasdaq compliance.

Lipella Pharmaceuticals reported a net loss of $1.44 million for the third quarter of 2024, with ongoing clinical development activities and Nasdaq compliance issues impacting the company.

Lipella Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting progress in clinical trials and ongoing research and development efforts.

Lipella Pharmaceuticals reported a net loss of $1.19 million for the first quarter of 2024 and is addressing a Nasdaq minimum bid price compliance issue.

Lipella Pharmaceuticals details its FY2024 financial results and progress in clinical trials for its lead drug candidates, LP-10 and LP-310, while addressing ongoing financial and Nasdaq compliance challenges.

Lipella Pharmaceuticals Inc. reports its 2023 financial results, highlighting progress in clinical development of its lead product candidates and ongoing research programs.

Jonathan Kaufman, a director, 10% owner, and officer of Lipella Pharmaceuticals, reported changes in beneficial ownership related to convertible preferred stock and warrants following the effectiveness of a registration statement.

Lipella Pharmaceuticals' CEO, Jonathan Kaufman, secures voting power over shares held by Spartan Capital Securities and its affiliates via an irrevocable proxy agreement.

Lipella Pharmaceuticals' CEO, Jonathan Kaufman, secures voting control over shares held by Spartan Capital Securities and its affiliates via an irrevocable proxy agreement.

Lipella Pharmaceuticals' CEO, Jonathan Kaufman, secures voting control over shares held by Spartan Capital Securities and its affiliates through an irrevocable proxy agreement.

Jonathan H. Kaufman, a director and officer of Lipella Pharmaceuticals, reported changes in his beneficial ownership of company securities following the effectiveness of a registration statement.

Lipella Pharmaceuticals has granted its CEO, Jonathan Kaufman, an irrevocable proxy to vote shares held by Spartan Capital Securities, related to consulting and placement agent agreements.

Lipella Pharmaceuticals adjourned its special stockholder meeting on December 20, 2024, due to the absence of a quorum and will reconvene on December 27, 2024.

Lipella Pharmaceuticals' special meeting of stockholders was adjourned due to a lack of quorum and will reconvene on December 20, 2024.

Lipella Pharmaceuticals is seeking stockholder approval to issue 20% or more of its common stock to secure an equity line of credit, aiming to regain compliance with Nasdaq's minimum equity requirement.

Lipella Pharmaceuticals is asking stockholders to approve a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and potentially improve stock marketability.

Jonathan H. Kaufman, President, CEO, and Chairman of Lipella Pharmaceuticals Inc., has filed an Amendment No. 18 to Schedule 13D, indicating he is no longer a beneficial owner of more than five percent of the company's common stock.

Dr. Michael B. Chancellor, Chief Medical Officer and Director of Lipella Pharmaceuticals Inc., has filed an Amendment No. 9 to Schedule 13D, indicating he has ceased to be a beneficial owner of more than five percent of the company's common stock.

Lipella Pharmaceuticals Inc. CEO Jonathan H. Kaufman's beneficial ownership filing reveals an updated stake of 8.0% and the termination of a significant proxy agreement with Spartan Capital Securities following the SEC's declaration of effectiveness for a resale registration statement.

Lipella Pharmaceuticals Inc. has disclosed an irrevocable proxy granted by Spartan Capital Securities, LLC to CEO Dr. Jonathan Kaufman, giving him voting control over shares issued as compensation for advisory and placement agent services.

Lipella Pharmaceuticals Inc. has disclosed an irrevocable proxy agreement granting its CEO, Dr. Jonathan Kaufman, voting control over a significant block of shares issued to Spartan Capital Securities, LLC, stemming from consulting and placement agent agreements.

Lipella Pharmaceuticals Inc. has filed an Amendment No. 14 to its Schedule 13D, detailing an irrevocable proxy agreement granting CEO Dr. Jonathan Kaufman voting control over significant shares issued to Spartan Capital Securities, LLC.

Leaf Huang has filed an Amendment No. 3 to Schedule 13G, indicating a reduction in beneficial ownership of Lipella Pharmaceuticals Inc. common stock to 2.7%, ceasing to be a 5% beneficial owner.

Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have jointly reported a 4.9% beneficial ownership stake in Lipella Pharmaceuticals Inc. common stock as of December 31, 2024.